Vasopressin V2-Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure - Vasopressin V2-Receptor Blockade With Tolvaptan in Patients With CHF

Description:

The goal of the trial was to compare three doses of tolvaptan, a novel, oral, nonpeptide vasopressin V2-receptor antagonist, with placebo on body weight in patients with chronic heart failure (CHF).